Zoetis Inc

ZTS-N

Get Alerts93 watching

NYSE:ZTS

169.07
1.08 (0.63%)
Zoetis, Inc. is the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of ...
More at Wikipedia
ZTS Fundamental Data  by TradingView
ZTS Chart  by TradingView
Technical Analysis for ZTS  by TradingView

Analysis and Opinions about ZTS-N

Signal
Opinion
Expert
Chart
BUY
BUY
Zoetis Inc (ZTS-N)
April 6, 2021
It's had a strong run during Covid, though it's perceived as a pandemic stock. Their livestock division has hurt because restaurants are closed, so there's less demand. This division grows only at 5% anyway, but there's higher growth in their pets division. The average pet costs $3,000 annually in food and medical supplies/services. Bringing such products to market is faster than for humans, and ZTS is bringing such products to market in the next little while. The stock is taking a breather here, but he continues to buy it and it will grow nicely in coming years.
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
April 6, 2021
It's had a strong run during Covid, though it's perceived as a pandemic stock. Their livestock division has hurt because restaurants are closed, so there's less demand. This division grows only at 5% anyway, but there's higher growth in their pets division. The average pet costs $3,000 annually in food and medical supplies/services. Bringing such products to market is faster than for humans, and ZTS is bringing such products to market in the next little while. The stock is taking a breather here, but he continues to buy it and it will grow nicely in coming years.
Consumer Products
Paul Harris, CFA
Price
$156.180
Owned
Yes
TOP PICK
TOP PICK
Zoetis Inc (ZTS-N)
March 4, 2021
Animal care plus livestock. Livestock is not growing as quickly as last year, but will as protein consumption grows in developing countries. Pet business really strong this year. Drugs come to market sooner, and not many generics. Great demographic and growth story. Yield is 0.67%. (Analysts’ price target is $186.31)
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
March 4, 2021
Animal care plus livestock. Livestock is not growing as quickly as last year, but will as protein consumption grows in developing countries. Pet business really strong this year. Drugs come to market sooner, and not many generics. Great demographic and growth story. Yield is 0.67%. (Analysts’ price target is $186.31)
Consumer Products
Paul Harris, CFA
Price
$143.710
Owned
Yes
WAIT
WAIT
Zoetis Inc (ZTS-N)
February 25, 2021
He took profits. Makes sense long-term. Valuation is getting heavy at 36x earnings, for an EPS growth rate of 11-12%. A lot of money has gone into biotech, so this has suffered. If the valuation came down, he'd revisit.
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
February 25, 2021
He took profits. Makes sense long-term. Valuation is getting heavy at 36x earnings, for an EPS growth rate of 11-12%. A lot of money has gone into biotech, so this has suffered. If the valuation came down, he'd revisit.
Consumer Products
Stan Wong
Price
$156.515
Owned
No
BUY
BUY
Zoetis Inc (ZTS-N)
February 12, 2021
They report Tuesday. He expects another winning quarter for this pet stock. He likes the pet healthcare business.
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
February 12, 2021
They report Tuesday. He expects another winning quarter for this pet stock. He likes the pet healthcare business.
Consumer Products
Jim Cramer - Mad Money
Price
$166.710
Owned
Unknown
TOP PICK
TOP PICK
Zoetis Inc (ZTS-N)
January 27, 2021
In 2001, people spent $6.2 billion on pets and $15.5 billion in 2018, so this is a good growth industry. Zoetis has a livestock business, growing 4--5%; though restaurant closures have slowed growth lately, as people age, they eat more protein. Also the pet business is growing strongly. The average pet owner spends $3,000 on their pet. Another tailwind is that animal drugs have few generics. (Analysts’ price target is $181.18)
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
January 27, 2021
In 2001, people spent $6.2 billion on pets and $15.5 billion in 2018, so this is a good growth industry. Zoetis has a livestock business, growing 4--5%; though restaurant closures have slowed growth lately, as people age, they eat more protein. Also the pet business is growing strongly. The average pet owner spends $3,000 on their pet. Another tailwind is that animal drugs have few generics. (Analysts’ price target is $181.18)
Consumer Products
Paul Harris, CFA
Price
$154.500
Owned
Yes
PARTIAL SELL
PARTIAL SELL
Zoetis Inc (ZTS-N)
January 14, 2021
Likes it in the long term. He's taken some profit. Short-term concern is that a lot of people bought pandemic companion animals, so 2020 was a really good year, and it's going to be hard to top 2020.
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
January 14, 2021
Likes it in the long term. He's taken some profit. Short-term concern is that a lot of people bought pandemic companion animals, so 2020 was a really good year, and it's going to be hard to top 2020.
Consumer Products
David Fingold
Price
$161.640
Owned
Unknown
BUY
BUY
Zoetis Inc (ZTS-N)
January 13, 2021
They make drugs for pets and livestock. Under the new CEO, ZTS is up 22% despite taking a beating during last year's lockdown. ZTS has since delivered a couple of strong quarters.
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
January 13, 2021
They make drugs for pets and livestock. Under the new CEO, ZTS is up 22% despite taking a beating during last year's lockdown. ZTS has since delivered a couple of strong quarters.
Consumer Products
Jim Cramer - Mad Money
Price
$161.950
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
Zoetis Inc (ZTS-N)
December 24, 2020
(A Top Pick Dec 19/19, Up 26%) Livestock and pets. Consistent grower at 5%. As people get wealthier, they tend to buy more protein, so livestock goes up. R&D benefits humans, has easier approval, and has pricing power. Pets are a high growth industry. Great products in pipeline. Will continue to do well.
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
December 24, 2020
(A Top Pick Dec 19/19, Up 26%) Livestock and pets. Consistent grower at 5%. As people get wealthier, they tend to buy more protein, so livestock goes up. R&D benefits humans, has easier approval, and has pricing power. Pets are a high growth industry. Great products in pipeline. Will continue to do well.
Consumer Products
Paul Harris, CFA
Price
$160.720
Owned
Yes
BUY
BUY
Zoetis Inc (ZTS-N)
October 26, 2020
A lot more people have either bought or adopted pets. The cost of keeping an animal has gotten more expensive. You should buy on a pull back. It is a great demographic story.
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
October 26, 2020
A lot more people have either bought or adopted pets. The cost of keeping an animal has gotten more expensive. You should buy on a pull back. It is a great demographic story.
Consumer Products
Paul Harris, CFA
Price
$160.700
Owned
Yes
HOLD
HOLD
Zoetis Inc (ZTS-N)
October 21, 2020
He took profits to switch into biotech. Revenue streams will grow at high single digits. Chart looks good. One of his favourite names in the space.
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
October 21, 2020
He took profits to switch into biotech. Revenue streams will grow at high single digits. Chart looks good. One of his favourite names in the space.
Consumer Products
Stan Wong
Price
$161.610
Owned
No
PAST TOP PICK
PAST TOP PICK
Zoetis Inc (ZTS-N)
August 20, 2020
(A Top Pick Sep 26/19, Up 26%) Pharmaceuticals for pets and livestock. Beat revenue by 11% on pets. Livestock side was down, but rose at 5%. Great company and demographic growth. If you see a pullback, buy.
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
August 20, 2020
(A Top Pick Sep 26/19, Up 26%) Pharmaceuticals for pets and livestock. Beat revenue by 11% on pets. Livestock side was down, but rose at 5%. Great company and demographic growth. If you see a pullback, buy.
Consumer Products
Paul Harris, CFA
Price
$158.600
Owned
Yes
HOLD
HOLD
Zoetis Inc (ZTS-N)
August 7, 2020
An animal health company. He has concerns over livestock exposure, especially with people wanting less chemicals and antibiotics in livestock. The pet market side of the business is more positive.
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
August 7, 2020
An animal health company. He has concerns over livestock exposure, especially with people wanting less chemicals and antibiotics in livestock. The pet market side of the business is more positive.
Consumer Products
Shane Obata
Price
$158.880
Owned
No
TOP PICK
TOP PICK
Zoetis Inc (ZTS-N)
June 26, 2020
An animal health care company that works with pets and livestock. There is over $15 billion in pet spending in the US today. There is not the same price pressure in pet health from insurance companies like in pharma. Getting a drug for a pet is easier and faster than for human use. On the livestock side, developing countries are consuming more protein. Yield 0.59% (Analysts’ price target is $136.14)
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
June 26, 2020
An animal health care company that works with pets and livestock. There is over $15 billion in pet spending in the US today. There is not the same price pressure in pet health from insurance companies like in pharma. Getting a drug for a pet is easier and faster than for human use. On the livestock side, developing countries are consuming more protein. Yield 0.59% (Analysts’ price target is $136.14)
Consumer Products
Paul Harris, CFA
Price
$133.980
Owned
Yes
PAST TOP PICK
PAST TOP PICK
Zoetis Inc (ZTS-N)
May 11, 2020
(A Top Pick May 21/19, Up 24%) Pets as well as livestock. There is not a lot of generics for pet drugs. A lot are the same as for pets as for humans.
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
May 11, 2020
(A Top Pick May 21/19, Up 24%) Pets as well as livestock. There is not a lot of generics for pet drugs. A lot are the same as for pets as for humans.
Consumer Products
Paul Harris, CFA
Price
$126.390
Owned
Yes
PAST TOP PICK
PAST TOP PICK
Zoetis Inc (ZTS-N)
March 12, 2020
(A Top Pick May 21/19, Up 18%) Pharma company for animals, livestock and pets. Great story. Great company and an opportunity to do well.
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
March 12, 2020
(A Top Pick May 21/19, Up 18%) Pharma company for animals, livestock and pets. Great story. Great company and an opportunity to do well.
Consumer Products
Paul Harris, CFA
Price
$120.280
Owned
Yes
Showing 1 to 15 of 37 entries
Next Page

Zoetis Inc(ZTS-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 7

Neutral - Hold Signals / Votes : 2

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 10

Stockchase rating for Zoetis Inc is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Zoetis Inc(ZTS-N) Frequently Asked Questions

What is Zoetis Inc stock symbol?

Zoetis Inc is a American stock, trading under the symbol ZTS-N on the New York Stock Exchange (ZTS). It is usually referred to as NYSE:ZTS or ZTS-N

Is Zoetis Inc a buy or a sell?

In the last year, 10 stock analysts published opinions about ZTS-N. 7 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is BUY. Read the latest stock experts' ratings for Zoetis Inc.

Is Zoetis Inc a good investment or a top pick?

Zoetis Inc was recommended as a Top Pick by Paul Harris, CFA on 2021-04-06. Read the latest stock experts ratings for Zoetis Inc.

Why is Zoetis Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Zoetis Inc worth watching?

10 stock analysts on Stockchase covered Zoetis Inc In the last year. It is a trending stock that is worth watching.

What is Zoetis Inc stock price?

On 2021-04-22, Zoetis Inc (ZTS-N) stock closed at a price of $169.07.

PixFuture exclusive partner.
© Stockchase Inc.